Market Cap 21.35M
Revenue (ttm) 0.00
Net Income (ttm) -24.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 207,784
Avg Vol 472,920
Day's Range N/A - N/A
Shares Out 14.24M
Stochastic %K 25%
Beta 1.66
Analysts Strong Sell
Price Target $40.17

Latest News on ANVS

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 6 weeks ago

Annovis to Host Patients' Live Forum on February 27, 2025


Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 2 months ago

Annovis Bio, Inc. Announces Proposed Public Offering


/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 4 months ago

/C O R R E C T I O N -- Today's Marketplace/


Annovis to Host Year-End Investor Webcast on December 11, 2024

Nov 25, 2024, 8:00 AM EST - 4 months ago

Annovis to Host Year-End Investor Webcast on December 11, 2024


Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 4:13 PM EDT - 9 months ago

Annovis stock more than doubled on Tuesday: what happened?


Annovis Announces New Publication in a Peer-Reviewed Journal

May 21, 2024, 7:30 AM EDT - 11 months ago

Annovis Announces New Publication in a Peer-Reviewed Journal


Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

May 6, 2024, 7:30 AM EDT - 11 months ago

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders


Annovis Bio to Participate in the 139th Yale CEO Summit

Dec 11, 2023, 1:00 PM EST - 1 year ago

Annovis Bio to Participate in the 139th Yale CEO Summit


Annovis Bio Appoints Andrew Walsh as Vice President Finance

Dec 1, 2023, 7:30 AM EST - 1 year ago

Annovis Bio Appoints Andrew Walsh as Vice President Finance